Abstracts tagged "Biologic drugs"

Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
René-Marc Flipo ¹, Florence Tubach ², Jean Ouaniche ³, Philippe Goupille⁴, Eric Lespessailles ⁵, Najat Gouyette ⁶, Naoual Harid ⁷, Jean-Marie Fayette ⁸, Philippe Bertin ⁹ and Bruno Fautrel ¹⁰, ¹Roger Salengro University-Hospital, Lille , France, Lille, France, ²Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³Private Practice , Toulon, France, Toulon, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Orléans Regional Hospitals, Orléans ,France, Orléans, France, ⁶MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, ⁷MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, ⁸ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, ⁹Limoges University-Hospital , Limoges, France, Limoges, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…
Abstract Number: 1511 • 2019 ACR/ARP Annual Meeting
Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients
Jean-Guillaume Letarouilly¹, Benoit Flachaire ², Céline Labadie ³, Jérémie Sellam ⁴, Pascal Richette ⁵, Philippe Dieudé ⁶, Pascal Claudepierre ⁷, Bruno Fautrel ⁸, Eric Houvenagel ⁹, Chi Duc Nguyen ¹⁰, Marie-Hélène Guyot ¹¹, Nicolas Segaud ¹², Frédéric Maury ¹³, Laurent Marguerie ¹⁴, Xavier Deprez ¹⁵, Jean-Hugues Salmon ¹⁶, Guy Baudens ¹⁷, Elisabeth Gervais ¹⁸, Isabelle Chary-Valckenaere ¹⁹, Pierre Lafforgue ²⁰, Damien Loeuille ²¹, Christophe Richez ²², Thao Pham ²⁰ and René-Marc Flipo ²³, ¹University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, ²Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, ³Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, ⁴Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, ⁵Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, ⁶Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, ⁷Rheumatology, CHU Henri Mondor Créteil, Paris, France, ⁸Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁹Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, ¹⁰Rheumatology, Hospital of Béthune, Béthune, Béthune, France, ¹¹Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, ¹²Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, ¹³Rheumatology, Private Practice, Beuvry, Beuvry, France, ¹⁴Rheumatology, Calot Institute, Berck, Berck-sur-Mer, ¹⁵Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, ¹⁶Rheumatology, Reims University Hospital, Reims, Reims, France, ¹⁷Rheumatology, Private Practice, Valenciennes, Valenciennes, France, ¹⁸CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁹Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ²⁰Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²¹Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, ²²Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ²³University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France
Background/Purpose: Ustekinumab (UST) is a new biological Disease-modifying AntiRheumatic Drug (bDMARD) available in psoriatic arthritis (PsA), targeting respectively IL12-23. Real-world data are missing for this…
Abstract Number: 1529 • 2019 ACR/ARP Annual Meeting
The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Sadettin Uslu¹, Gercek Can ², Ayşe Cefle ³, Sema Yılmaz ⁴, Sinem Burcu Kocaer ⁵, Tuba Yüce İnel ¹, Semih Gülle ¹, Süleyman Serdar Koca ⁶, Servet Yolbaş ⁷, Mehmet Akif Öztürk ⁸, Soner Senel ⁹, Nevsun Inanc ¹⁰, Ediz Dalkılıç ¹¹, Ozgül Gunduz ¹², Abdurrahman Tufan ⁸, Servet Akar ¹³, Merih Birlik ⁵, Ismail Sari ¹, Nurullah Akkoç ¹² and Fatos Onen ¹⁴, ¹Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, ²Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ³Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁴Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ⁵Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, ⁶Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁷Division of Rheumatology, Inonu University School of Medicine, Malatya, Turkey, Malatya, Turkey, ⁸Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁹Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁰Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ¹¹Uludağ University, Bursa, Turkey, ¹²Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ¹³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁴Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this…
Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting
Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…
Abstract Number: 2111 • 2019 ACR/ARP Annual Meeting
Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
Alexander Peck¹, Ella Starobinska ², Gilbert Ortega ¹, Travis Maestas ¹, Jaclyn Leong ¹, Phan Saligrama ¹, Jawad Bilal ¹ and Dominick Sudano ³, ¹University of Arizona College of Medicine, Tucson, AZ, ²University of Arizona College of Medicine, Tucson, AL, ³Banner University Medical Center Tucson, Tucson
Background/Purpose: Studies have shown an increased risk of coccidioidomycosis infection in immunosuppressed patients. However, relationship of coccidioidomycosis infections with different immunosuppressive medication is not well…
Abstract Number: 593 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
Sebastian C Rodriguez-Garcia¹, Raul Castellanos-Moreira Sr.¹, José Inciarte-Mundo², M. Victoria Hernández³, Virginia Ruiz-Esquide², Andrea Cuervo¹, Julio Ramírez², Juan Cañete¹, Jose Gomez Puerta¹ and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain
Background/Purpose: Recommendations and guidelines for the management of Rheumatoid Arthritis (RA) and spondyloarthritis (SpA) with bDMARD include dose-tapering as an adequate option for patients on…
Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Jeffrey R. Curtis¹, Gregory St. John², Michael Pannucci², Yong Lin³, José A. Maldonado-Cocco⁴, Tom W.J. Huizinga⁵, Marina Stanislav⁶ and Paul Emery⁷, ¹University of Alabama, Birmingham, AL, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Universidad de Buenos Aires, Buenos Aires, Argentina, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…
Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Sarah L. Patterson¹, Michael Evans², Ishita Aggarwal³, Zara Izadi⁴, Milena Gianfrancesco⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California - San Francisco, San Francisco, CA, ³Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶San Francisco VA Medical Center, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
Abstract Number: 626 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis
Maria A. Lopez-Olivo¹, Aliza Matusevich², Scott B. Cantor³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ³Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Data on patient-reported functional ability to evaluate the optimal strategy for patients who have failed to first TNFi is scarce. Patient-reported outcomes are a…
Abstract Number: 2044 • 2018 ACR/ARHP Annual Meeting
Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies
Ivan Arias de la Rosa¹, Patricia Ruiz-Limon¹, Carlos Perez-Sanchez², Maria Carmen Abalos-Aguilera¹, Yolanda Jiménez-Gómez², Irene Cecchi³, Rafaela Ortega-Castro², Miguel Angel Caracuel-Ruiz⁴, Jerusalem Calvo-Gutierrez², Alejandro Escudero-Contreras¹, Eduardo Collantes-Estévez², Chary Lopez-Pedrera⁴ and Nuria Barbarroja², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: Neutrophils are the most abundant cells in synovial fluid, having all the features of activated cells in rheumatoid arthritis (RA), including prolonged cell survival,…
Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Gregory St. John², Carol J. Etzel¹, Stefano Fiore³, Taylor Blachley¹, Toshio Kimura², Rajeshwari Punekar³, Kelechi Emeanuru⁴, Susan Boklage² and Joel Kremer^1,5, ¹Corrona LLC, Waltham, MA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi, Bridgewater, NJ, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…
Abstract Number: 627 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis
Burcu Yagız¹, Belkıs Nihan Coşkun², Sedat Kiraz³, Ihsan Ertenli⁴, Orhan Kucuksahin⁵, Ediz Dalkiliç⁶, Cemal Bes⁷, Nilufer Alpay Kanitez⁸, Timucin Kasifoglu⁹, Hakan Emmungil¹⁰, Pamir Atagunduz¹¹, Suleyman Serdar Koca¹², Muhammet Cinar¹³, Aşkın Ateş¹⁴, Servet Akar¹⁵, Onay Gercik¹⁶, Duygu Ersozlu Bakirli¹⁷, Veli Yazisiz¹⁸, Gezmis Kimyon¹⁹, Nazife Sule Yasar Bilge²⁰, Muge Aydin Tufan²¹, Ridvan Mercan²², Burak Oz¹², Zeynel Abidin Akar¹², Omer Karadag²³, Bahar Kelesoglu²⁴, Sedat Yılmaz²⁵, Sezin Turan²⁶, Yavuz Pehlivan², Ender Terzioglu²⁷, Levent Kilic²³, Sukran Erten²⁸, Koray Tascilar²⁹ and Umut Kalyoncu³⁰, ¹Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ²Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ⁴Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ⁵Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁶Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁷Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁸Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, ⁹Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ¹⁰Department of Internal Medicine, Division of Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ¹¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ¹²Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ¹³Division of Rheumatology, Gülhane Military Medical Academy, School of Medicine, Ankara, Turkey, ¹⁴Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ¹⁵Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹⁶Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹⁷PsART study group, Adana, Turkey, ¹⁸Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁹Rheumatology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, ²⁰Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ²¹Rheumatology, Cukurova University School of Medicine, Adana, Turkey, ²²Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ²³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²⁴Rheumatology, Ankara University, Ankara, Turkey, ²⁵Division of Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, ²⁶Trakya University Medical Faculty, Edirne, Turkey, ²⁷Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ²⁸PsART study group, Ankara, Turkey, ²⁹Rheumatology, Okmeydani Research and Training Hospital, Istanbul, Turkey, ³⁰Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory, systemic autoimmune disease that causes several health problems, such as pain, joint destruction and loss of function.…
Abstract Number: 2078 • 2018 ACR/ARHP Annual Meeting
Induction of Netosis in Ankylosing Spondylitis: Association to Disease Pathogenesis and Modulation By Anti-Tnfα Therapy
Patricia Ruiz-Limon¹, M. Carmen Castro-Villegas², Chary Lopez-Pedrera³, Rafaela Ortega-Castro⁴, Maria Carmen Abalos-Aguilera¹, Nuria Barbarroja⁴, Carlos Perez-Sanchez⁴, Ivan Arias de la Rosa¹, Alejandro Ibáñez-Costa³, Alejandra Maria Patiño-Trives³, Daniel Espejo-Peralbo¹, Pilar Font-Ugalde⁴, Jose Antonio Gonzalez-Reyes⁵, Jose Manuel Villalba⁵, Clementina López-Medina⁴, Alejandro Escudero-Contreras¹, Eduardo Collantes-Estévez⁴ and Yolanda Jiménez-Gómez⁴, ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Departamento de Biologia Celular, Fisiologia e Inmunología, University of Córdoba, Cordoba, Spain
Background/Purpose: NETosis has been suggested to play a central role in several rheumatology diseases. Nevertheless, this process, and its modulation in therapeutic response has not…
Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Daeria O. Lawson^1,2, Maria Eraso³, Lawrence Mbuagbaw⁴, Theresa Aves⁵, Alvin Leenus⁴, Marianinha Joanes⁶, Ahmed Omar^1,7 and Robert D Inman^8,9, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, Tornoto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ⁵St. Michael's Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Boston University School of Medicine, Boston, MA, United States, Boston, MA, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…
Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Magali Pacanowski Fournier¹, Antoine Brezin², Christophe Chiquet Sr.³, David Saadoun⁴, Jeremie Sellam⁵, Patrice Cacoub⁶, Pascal Sève⁷, Bahram Bodaghi Sr.⁸ and Laurent Kodjikian Sr.^9,10,11, ¹medical department, Magali Pacanowski Fournier is employee of AbbVie and own AbbVie stock, Rungis, France, ²Ophtalmology, Referral Center for Rare Ophthalmological Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, ophtalmology, France, Paris, France, ³ophtalmology, CHU-Grenoble-Alpes, La Tronche, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁷Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁸ophtalmology, Hôpital La Pitié-Salpêtrière; Université Sorbonne, paris, France, ⁹ophtalmology, Chu de La Croix-Rousse, hospices civils de Lyon, Lyon, France, ¹⁰université Claude Bernard lyon 1, villeurbanne, France, ¹¹UMR-CNRS 5510 Matéis, villeurbanne, France
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…